Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Via Respimat® Inhaled BI 1744 CL Compared to Moxifloxacin and Placebo in Healthy Male and Female Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Moxifloxacin (Avalox®)
Drug: BI 1744 CL solution for inhalation
Drug: Placebo matching BI 1744 CL

First Posted Date: 2014-06-24

Last Posted Date: 2014-06-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 24

Registration Number: NCT02172144

BI 1744 CL in Patients With Severe Renal Impairment in Comparison to Subjects With Normal Renal Function

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1774 CL

First Posted Date: 2014-06-24

Last Posted Date: 2014-06-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 22

Registration Number: NCT02172118

Relative Bioavailability and Pharmacodynamics of Dabigatran With Enoxaparin in Healthy Male and Female Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Enoxaparin prefilled syringes
Drug: Dabigatran etexilate capsules

First Posted Date: 2014-06-24

Last Posted Date: 2014-06-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 29

Registration Number: NCT02171559

BIBW 2992 in Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: BIBW 2992

First Posted Date: 2014-06-24

Last Posted Date: 2014-06-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 7

Registration Number: NCT02171650

Safety, Pharmacodynamics and Pharmacokinetics After Single Oral Administration of Dabigatran Etexilate Capsule in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Dabigatran etexilate high dose
Drug: Dabigatran etexilate low dose
Drug: Dabigatran etexilate medium dose
Drug: Placebo

First Posted Date: 2014-06-24

Last Posted Date: 2014-06-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 10

Registration Number: NCT02171455

Bioequivalence of Two Different Polymorphs of Dabigatran Etexilate in Healthy Male and Female Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Dabigatran etexilate polymorph II
Drug: Dabigatran etexilate polymorph I

First Posted Date: 2014-06-24

Last Posted Date: 2014-06-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 66

Registration Number: NCT02171481

Comparative Pharmacokinetics and Pharmacodynamics of Tiotropium With Ipratropium or Placebo After 19 Days of Tiotropium Treatment

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Ipratropium - unit dose vial
Drug: Tiotropium - inhalation capsule
Drug: Placebo matching tiotropium
Drug: Placebo matching ipratropium

First Posted Date: 2014-06-24

Last Posted Date: 2014-06-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 36

Registration Number: NCT02172781

Metabolism and Pharmacokinetics of [14C]-BIBR 953 ZW After Administration of Single Doses of [14C]-BIBR 953 ZW Intravenously or [14C]-BIBR 1048 Oral Solution in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BIBR 953 ZW Intravenously
Drug: BIBR 1048 Oral Solution

First Posted Date: 2014-06-24

Last Posted Date: 2014-06-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 10

Registration Number: NCT02171442

Dose Ranging Study of Ba 679 BR Inhalation Powder in Chronic Obstructive Pulmonary Disease (COPD) Patients

Phase 2

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Placebo inhalation powder
Drug: Ba 679 BR low dose
Drug: Ba 679 BR middle dose
Drug: Ba 679 BR high dose

First Posted Date: 2014-06-24

Last Posted Date: 2014-06-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 28

Registration Number: NCT02172352

Dose Escalation Study of Oral Treatment With BIBW 2992 in Patients With Advanced Solid Tumours

Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: BIBW 2992

First Posted Date: 2014-06-24

Last Posted Date: 2014-06-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 53

Registration Number: NCT02171702

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy